Adaptive Biotechnologies (ADPT) Depreciation and Depletion (2018 - 2026)

Adaptive Biotechnologies has reported Depreciation and Depletion for 9 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Depreciation and Depletion fell 20.73% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (down 10.74% YoY) and the FY2025 annual result came in at $16.1 million, down 8.08% from the prior year.
• Depreciation and Depletion declined to $3.4 million in Q1 2026 per ADPT's latest filing, from $3.8 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $5.3 million in Q3 2023 and troughed at $3.4 million in Q1 2026.
• A 5-year average of $4.5 million and a median of $4.6 million in 2022 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2022 and 2024: Depreciation and Depletion surged 105.91% in 2022, then decreased 21.97% in 2024.
• Over 5 years, Depreciation and Depletion stood at $4.9 million in 2022, then increased by 1.52% to $4.9 million in 2023, then decreased by 18.47% to $4.0 million in 2024, then slipped by 6.32% to $3.8 million in 2025, then retreated by 9.24% to $3.4 million in 2026.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $3.4 million, $3.8 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.